Marianne Sponer Muhlebach1, Valeria Beckett2, Elena Popowitch3, Melissa B Miller3, Arthur Baines2, Nicole Mayer-Hamblett2,4, Edith T Zemanick5, Wynton C Hoover6, Jill M VanDalfsen2, Preston Campbell7, Christopher H Goss2,4,8. 1. Department of Pediatrics, University of North Carolina, Chapel Hill, North Carolina, USA. 2. Seattle Children's Research Institute, Seattle, Washington, USA. 3. Department of Microbiology, University of North Carolina, Chapel Hill, North Carolina, USA. 4. Department of Pediatrics, University of Washington, Seattle, Washington, USA. 5. Department of Pediatrics, University of Colorado School of Medicine, Denver, Colorado, USA. 6. Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA. 7. Cystic Fibrosis Foundation, Bethesda, Maryland, USA. 8. Department of Medicine, University of Washington, Seattle, Washington, USA.
Abstract
OBJECTIVE: To evaluate microbiological effectiveness, that is, culture negativity of a non-blinded eradication protocol (Rx) compared with observation (Obs) in clinically stable cystic fibrosis participants with newly positive methicillin resistant Staphylococcusaureus (MRSA) cultures. DESIGN: This non-blinded trial randomised participants ages 4-45 years with first or early (≤2 positive cultures within 3 years) MRSA-positive culture without MRSA-active antibiotics within 4 weeks 1:1 to Rx or Obs. The Rx protocol was: oral trimethoprim-sulfamethoxazole or if sulfa-allergic, minocycline plus oral rifampin; chlorhexidine mouthwash for 2 weeks; nasal mupirocin and chlorhexidine body wipes for 5 days and environmental decontamination for 21 days. The primary end point was MRSA culture status at day 28. RESULTS:Between 1 April 2011 to September 2014, 45 participants (44% female, mean age 11.5 years) were randomised (24 Rx, 21 Obs). At day 28, 82% (n=18/22) of participants in the Rx arm compared with 26% (n=5/19) in the Obs arm were MRSA-negative. Adjusted for interim monitoring, this difference was 52% (95% CI 23% to 80%, p<0.001). Limiting analyses to participants who were MRSA-positive at the screening visit, 67% (8/12) in the Rx arm and 13% (2/15) in the Obs arm were MRSA-negative at day 28, adjusted difference: 49% (95% CI 22% to 71%, p<0.001). Fifty-four per cent in the Rx arm compared with 10% participants in the Obs arm remained MRSA-negative through day 84. Mild gastrointestinal side effects were higher in the Rx arm. CONCLUSIONS: This MRSA eradication protocol for newly acquired MRSA demonstrated microbiological efficacy with a large treatment effect. TRIAL REGISTRATION NUMBER: NCT01349192. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
RCT Entities:
OBJECTIVE: To evaluate microbiological effectiveness, that is, culture negativity of a non-blinded eradication protocol (Rx) compared with observation (Obs) in clinically stable cystic fibrosisparticipants with newly positive methicillin resistant Staphylococcusaureus (MRSA) cultures. DESIGN: This non-blinded trial randomised participants ages 4-45 years with first or early (≤2 positive cultures within 3 years) MRSA-positive culture without MRSA-active antibiotics within 4 weeks 1:1 to Rx or Obs. The Rx protocol was: oral trimethoprim-sulfamethoxazole or if sulfa-allergic, minocycline plus oralrifampin; chlorhexidine mouthwash for 2 weeks; nasal mupirocin and chlorhexidine body wipes for 5 days and environmental decontamination for 21 days. The primary end point was MRSA culture status at day 28. RESULTS: Between 1 April 2011 to September 2014, 45 participants (44% female, mean age 11.5 years) were randomised (24 Rx, 21 Obs). At day 28, 82% (n=18/22) of participants in the Rx arm compared with 26% (n=5/19) in the Obs arm were MRSA-negative. Adjusted for interim monitoring, this difference was 52% (95% CI 23% to 80%, p<0.001). Limiting analyses to participants who were MRSA-positive at the screening visit, 67% (8/12) in the Rx arm and 13% (2/15) in the Obs arm were MRSA-negative at day 28, adjusted difference: 49% (95% CI 22% to 71%, p<0.001). Fifty-four per cent in the Rx arm compared with 10% participants in the Obs arm remained MRSA-negative through day 84. Mild gastrointestinal side effects were higher in the Rx arm. CONCLUSIONS: This MRSA eradication protocol for newly acquired MRSA demonstrated microbiological efficacy with a large treatment effect. TRIAL REGISTRATION NUMBER: NCT01349192. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Entities:
Keywords:
Bacterial Infection; Cystic Fibrosis; Infection Control
Authors: E Vanderhelst; E De Wachter; J Willekens; D Schuermans; W Vincken; A Malfroot; S Verbanck Journal: Acta Clin Belg Date: 2014-09-24 Impact factor: 1.264
Authors: Marianne S Muhlebach; Meredith Miller; Lisa M LaVange; Greg Mayhew; Jennifer S Goodrich; Melissa B Miller Journal: J Cyst Fibros Date: 2011-03-21 Impact factor: 5.482
Authors: Elliott C Dasenbrook; William Checkley; Christian A Merlo; Michael W Konstan; Noah Lechtzin; Michael P Boyle Journal: JAMA Date: 2010-06-16 Impact factor: 56.272
Authors: Miriam M Treggiari; George Retsch-Bogart; Nicole Mayer-Hamblett; Umer Khan; Michal Kulich; Richard Kronmal; Judy Williams; Peter Hiatt; Ronald L Gibson; Terry Spencer; David Orenstein; Barbara A Chatfield; Deborah K Froh; Jane L Burns; Margaret Rosenfeld; Bonnie W Ramsey Journal: Arch Pediatr Adolesc Med Date: 2011-09
Authors: Sonya L Heltshe; Lisa Saiman; Elena B Popowitch; Melissa B Miller; Margaret Kloster; Valeria Thompson; Thomas W Ferkol; Wynton C Hoover; Michael S Schechter; Marianne S Muhlebach Journal: J Pediatric Infect Dis Soc Date: 2014-06-09 Impact factor: 3.164
Authors: Clement L Ren; Wayne J Morgan; Michael W Konstan; Michael S Schechter; Jeffrey S Wagener; Kathryn A Fisher; Warren E Regelmann Journal: Pediatr Pulmonol Date: 2007-06
Authors: Gabriela R Oates; William T Harris; Steven M Rowe; George M Solomon; Suranjana Dey; Aowen Zhu; Wynton C Hoover; Hector H Gutierrez Journal: Pediatr Infect Dis J Date: 2019-11 Impact factor: 2.129
Authors: Sachinkumar B Singh; Amanda J McLearn-Montz; Francesca Milavetz; Levi K Gates; Christopher Fox; Logan T Murry; Ashley Sabus; Harry S Porterfield; Anthony J Fischer Journal: Pediatr Pulmonol Date: 2019-04-22
Authors: Giovanni Taccetti; Michela Francalanci; Giovanna Pizzamiglio; Barbara Messore; Vincenzo Carnovale; Giuseppe Cimino; Marco Cipolli Journal: Antibiotics (Basel) Date: 2021-03-22
Authors: Peter H Gilligan; Damian G Downey; J Stuart Elborn; Patrick A Flume; Sebastian Funk; Deirdre Gilpin; Timothy J Kidd; John McCaughan; B Cherie Millar; Philip G Murphy; Jacqueline C Rendall; Michael M Tunney; John E Moore Journal: J Clin Microbiol Date: 2018-08-27 Impact factor: 5.948